| |
ASM/ICAAC: Superior Efficacy and Improved Renal and Bone Safety After Switching From a Tenofovir Disoproxil Fumarate Regimen to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment
|
| |
| |
Reported by Jules Levin
ASM/ICAAC 2016 June 16-20, Boston MA
Edwin DeJesus,1 Bernhard Haas,2 Sorana Segal-Maurer,3 Moti Ramgopal,4 Anthony Mills,5 Ya-Pei Liu,6 Scott McCallister6
1Orlando Immunology Center, Orlando, FL; 2Medizinische Universität Graz, Austria; 3NewYork-Presbyterian/Queens, Flushing, NY; 4Midway Immunology and Research Center, Fort Pierce, FL; 5Southern California Men's Medical Group, Los Angeles, CA; 6Gilead Sciences, Inc., Foster City, CA
|
|
| |
| |
|
|
|
